Open Access and Peer-reviewed Medical Journal
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal


Original Research 


Evaluation of the Kidney Disease Developed Malignancy Patients

Can Huzmeli.

Abstract
Background: Renal involvement in malignant patients may lead to kidney disease indirectly for a number of reasons, including direct metastasis or dehydration, hyperuricemia, and tumor lysis syndrome. We aimed to evaluate malignant patients who developed kidney disease in our study.
Method: This study was performed in malignant patients who applied to the Kahramanmaras Necip Fazil City hospital between 2015-2017. Blood urea nitrogen, serum creatinine, uric acid, sodium, potassium, calcium, phosphorus, glucose, complete urine output and hemogram were noted in patients with kidney disease.
Results: A total of 688 cancer patients were included in the study. 53.6% of the patients were female and 46.2% were male. The average age of the patients was found as 60.23±13.25 (21-94). Acute kidney injury was detected in %17,1. When the patients diagnosed with kidney disease were evaluated; serum uric acid levels were higher in 46.2% of patients, calcium-level was low in 7.7% of patients and high in 3.6% of patients, serum potassium level was high in 21.1% of patients, phosphorus level was high in 42.9% and serum sodium level was low in 17.2% of patients. According to Kidney Disease Improve Global Outcomes, the acute renal injury was detected in 42.4% of stage-I, 25.4% of stage II, and 32.2% of stage-III. 33 of 118 patients with acute renal injury died.
Conclusion: In our study, the incidence of acute renal injury was 17.1% in the cancer patients. The mortality rate was higher in the patients with the acute renal injury.

Key words: Malignancy, acute renal injury, glomerular filtration rate


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Can Huzmeli
on Google
on Google Scholar
Article Statistics
 Viewed: 511
Downloaded: 215
Cited: 0


How to Cite this Article
Pubmed Style

Can Huzmeli. Evaluation of the Kidney Disease Developed Malignancy Patients. Ulutas Med J. 2018; 4(2): 90-96. doi:10.5455/umj.20180323033247


Web Style

Can Huzmeli. Evaluation of the Kidney Disease Developed Malignancy Patients. http://www.ulutasmedicaljournal.com/?mno=294676 [Access: October 18, 2018]. doi:10.5455/umj.20180323033247


AMA (American Medical Association) Style

Can Huzmeli. Evaluation of the Kidney Disease Developed Malignancy Patients. Ulutas Med J. 2018; 4(2): 90-96. doi:10.5455/umj.20180323033247



Vancouver/ICMJE Style

Can Huzmeli. Evaluation of the Kidney Disease Developed Malignancy Patients. Ulutas Med J. (2018), [cited October 18, 2018]; 4(2): 90-96. doi:10.5455/umj.20180323033247



Harvard Style

Can Huzmeli (2018) Evaluation of the Kidney Disease Developed Malignancy Patients. Ulutas Med J, 4 (2), 90-96. doi:10.5455/umj.20180323033247



Turabian Style

Can Huzmeli. 2018. Evaluation of the Kidney Disease Developed Malignancy Patients. THE ULUTAS MEDICAL JOURNAL, 4 (2), 90-96. doi:10.5455/umj.20180323033247



Chicago Style

Can Huzmeli. "Evaluation of the Kidney Disease Developed Malignancy Patients." THE ULUTAS MEDICAL JOURNAL 4 (2018), 90-96. doi:10.5455/umj.20180323033247



MLA (The Modern Language Association) Style

Can Huzmeli. "Evaluation of the Kidney Disease Developed Malignancy Patients." THE ULUTAS MEDICAL JOURNAL 4.2 (2018), 90-96. Print. doi:10.5455/umj.20180323033247



APA (American Psychological Association) Style

Can Huzmeli (2018) Evaluation of the Kidney Disease Developed Malignancy Patients. THE ULUTAS MEDICAL JOURNAL, 4 (2), 90-96. doi:10.5455/umj.20180323033247








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


CrossRef

ScopeMed

Google Scholar

TUBITAK Dergipark

Index Scholar

Index Copernicus


ABOUT JOURNAL
POLICIES and STATEMENTS

The articles in Ulutas Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.